Contingent naloxone treatment of the narcotic addict: a pilot study.
In a community-based abstinence program, 108 chronic heroin abusers, paroled from Maryland correctional institutions, were administered the narcotic antagonist, naloxone, in escalating 500 mg dosages to a daily maximum dosage of 2,000 mg when either urine analysis indicated narcotic drug use or unexcused absences led to the suspicion of narcotic intake. Dosage was then continued at the maximum level until the record again indicated abstinence. This approach was regarded as such a distinct departure from customary antagonist administration that a pilot investigation of its effectiveness was undertaken. Six month outcome data on all patients were constrasted with those of an historical comparison group previously treated in the same clinic without naloxone administration. Both groups were equivalent on all criminal history, demographic, and prognostic variables. The group receiving contingent naloxone administration showed a significantly lower institutionalization rate (8%) than that for the reference sample (37%). Complete abstinence rates were also in favor of the naloxone group (38 vs. 12%).
D000041:Absenteeism; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D006556:Heroin Dependence / Q000534:rehabilitation*; D006801:Humans; D008297:Male; D008396:Maryland; D008875:Middle Aged; D009270:Naloxone / Q000008:administration & dosage* / Q000627:therapeutic use; D010352:Patient Dropouts; D010865:Pilot Projects; D011329:Prisoners; D012008:Recurrence; D012054:Reinforcement, Psychology
D009270:Naloxone